Associated Genetic Biomarkers

Overview

NCI Definition: An infiltrating adenocarcinoma that arises from the epithelial cells of the pancreas. It affects males more often than females and the patients are usually over 50 years of age. Microscopically it is characterized by the presence of glandular (ductal) differentiation and desmoplastic stroma formation. Signs and symptoms include pain, loss of weight, and jaundice. It grows rapidly and is usually detected after it has metastasized to other anatomic sites. The prognosis is usually poor. [1]

Pancreatic ductal adenocarcinomas most frequently harbor alterations in KRAS, TP53, and CDKN2A [2].

Most Commonly Altered Genes in Pancreatic Ductal Adenocarcinoma

KRAS Mutation, TP53 Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, and TP53 Frameshift are the most common alterations in pancreatic ductal adenocarcinoma [2].

Top Alterations in Pancreatic Ductal Adenocarcinoma

Significant Genes in Pancreatic Ductal Adenocarcinoma

ATM +

ATR +

BARD1 +

BRAF +

BRCA1 +

BRCA2 +

BRIP1 +

CDKN2A +

CHEK1 +

CHEK2 +

EGFR +

ERBB2 +

FANCA +

FANCB +

FANCC +

FANCD2 +

FANCE +

FANCF +

FANCG +

FANCI +

FANCL +

FANCM +

HRAS +

KRAS +

MCPH1 +

MLH1 +

MLH3 +

MRE11A +

MSH2 +

MSH3 +

MSH6 +

MTAP +

NBN +

NRAS +

PALB2 +

PMS1 +

PMS2 +

PTEN +

RAD50 +

RAD51 +

RAD51B +

RAD51C +

RAD51D +

SLX4 +

Disease Details

Synonyms
Ductal Adenocarcinoma of the Pancreas, Pancreatic Infiltrating Duct Carcinoma, Not Otherwise Specified, Ductal Adenocarcinoma of Pancreas, Pancreatic Tubular Adenocarcinoma, Pancreas Ductal Adenocarcinoma, Pancreatic Infiltrating Duct Carcinoma, NOS
Parent(s)
Pancreatic Adenocarcinoma
Children
Pancreatic Signet Ring Cell Carcinoma, Undifferentiated Pancreatic Carcinoma, Colloid Carcinoma of the Pancreas, and Pancreatic Foamy Gland Adenocarcinoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.